Ovid Therapeutics Q1 2022 Earnings Report
Key Takeaways
Ovid Therapeutics reported a revenue of $1.4 million and a net loss of $16.1 million for the first quarter ended March 31, 2022. The company's cash and cash equivalents were $166.7 million as of March 31, 2022, which is expected to support the advancement of its current epilepsy programs into 2025.
Ovid anticipates filing an IND for OV329 and initiating Phase 1 trials in the fourth quarter of 2022.
Data supporting OV329 in rare and treatment-resistant epilepsies expected to be presented at upcoming conferences.
Ovid entered into an agreement with Tufts University to support advancement of the pipeline.
Ovid expects its cash and cash equivalents to support advancement of its current epilepsy programs into 2025.
Ovid Therapeutics
Ovid Therapeutics
Forward Guidance
Ovid expects to file an IND for OV329 and initiate Phase 1 trials in the fourth quarter of 2022. Ovid expects its cash and cash equivalents to support advancement of its current epilepsy programs into 2025.